Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information

Rhea-AI Summary

Elite Pharmaceuticals (OTCQB: ELTP) reported third-quarter fiscal 2026 results for the three months ended December 31, 2025. Revenue was $31.6 million, up about 120% year-over-year. Income from operations was $9.0 million, up ~721%. Net income was $18.6 million.

The company attributed the profit increase primarily to sales of newly launched lisdexamfetamine and naltrexone products plus strong growth in Elite-label lines. Management will host a conference call on February 18, 2026 at 11:30 AM EST to discuss results and recent developments.

Positive

• Revenue $31.6M, up ~120% year-over-year
• Operating income $9.0M, up ~721% year-over-year
• Net income $18.6M reported for Q3 FY2026
• Growth driven by launches of lisdexamfetamine and naltrexone

Negative

• None.

Conference Call Scheduled for Wednesday, February 18 at 11:30 AM EST

Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter").

Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of $17.2 million or approximately 120% as compared to the comparable period of the prior fiscal year. Income from operations was $9.0 million, an increase of $7.9 million or approximately 721%, as compared to the comparable period of the prior fiscal year. The increase in operating profits was primarily attributed to sales of Elite's lisdexamfetamine and naltrexone products, which were launched after the comparable period of the prior fiscal year, as well as overall strong growth in the Elite label product lines as compared to the comparable period in the prior fiscal year. Net income was $18.6 million.

Conference Call Information

Elite's management will host a conference call to discuss the Third Quarter of Fiscal Year 2026 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.

Date:	February 18, 2026
Time:	11:30 AM EST
Dial-in numbers:	1-800-346-7359 (domestic) 1-973-528-0008 (international)
Conference number:	98840
Questions:	dianne@elitepharma.com Financial questions by 7:00 PM EST on Tuesday, February 17, 2026
Audio Replay:	https://elite.irpass.com/events_presentations

 

The financial statements can be viewed for Elite's Third Quarter of Fiscal Year 2026 on Form 10-Q here.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationwide under the Elite Laboratories, Inc. label. Elite also has products licensed to TAGI Pharma. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284226

FAQ

What were Elite Pharmaceuticals (ELTP) Q3 FY2026 revenues and growth?

Elite reported $31.6 million in Q3 FY2026 revenue, about 120% higher year-over-year. According to the company, growth was driven by recently launched lisdexamfetamine and naltrexone products plus stronger Elite-label sales.

How much operating profit did ELTP report for the quarter ended December 31, 2025?

Elite reported $9.0 million income from operations for the quarter, an increase of ~721% year-over-year. According to the company, higher sales of new product launches and Elite-label lines drove the operating profit gain.

When is Elite Pharmaceuticals' conference call for Q3 FY2026 and how can investors join?

The conference call is scheduled for February 18, 2026 at 11:30 AM EST. According to the company, domestic dial-in is 1-800-346-7359, international 1-973-528-0008 with conference number 98840 and an audio replay online.

What explained ELTP's net income of $18.6 million in Q3 FY2026?

Net income was $18.6 million for the quarter. According to the company, the gain primarily reflects sales of newly launched lisdexamfetamine and naltrexone products and overall strong growth in Elite-label product lines.